查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1561427

2024-2032 年宠物癌症治疗市场报告（按治疗方法、动物物种、癌症类型、最终用户和地区）

Pet Cancer Therapeutics Market Report by Therapy, Animal Species, Cancer Type, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3个工作天内

价格

2023年，全球宠物癌症治疗市场规模达2.952IMARC Group美元。宠物拥有率的提高和人类与动物之间的联繫、兽医学和研究的进步以及人们对宠物癌症疗法的可用性和益处的认识不断提高是推动市场的一些主要因素。

宠物癌症疗法是一种专门的医疗疗法和药物，旨在诊断、治疗和控制动物（尤其是狗和猫）的癌症。与人类癌症治疗类似，这些疗法可能包括化疗、放射治疗、免疫疗法、标靶治疗和安宁疗护。兽医肿瘤学家使用这些疗法来治疗宠物的各种癌症并提高它们的生活品质。随着兽医学的不断进步，宠物癌症疗法的可用性和有效性不断提高，使宠物主人能够为他们心爱的被诊断患有癌症的动物伙伴获得全面和富有同情心的护理。

由于宠物饲养量和人与动物关係的增加，宠物主人投资先进医疗（包括癌症治疗）的意愿不断增强，以确保动物伙伴的福祉，这将刺激预测期内市场的成长。此外，由于诊断能力的提高和寿命的延长，宠物癌症盛行率不断上升，增加了对有效和专业治疗的需求。除此之外，兽医肿瘤学和研究的许多进步，包括为宠物开发更有针对性和创新的癌症疗法，促进了市场的成长。此外，宠物主人对宠物癌症治疗的可用性和益处的认识不断提高，导致了早期检测和干预，推动了市场成长。此外，专门兽医肿瘤中心的建立以及兽医和人类肿瘤学家之间不断加强的合作，提高了宠物癌症护理的可及性和专业知识，也促进了市场的成长。

宠物癌症治疗市场趋势/驱动因素：

增加宠物饲养量和人与动物的联繫

宠物数量的增加和人类与动物关係的加强已成为宠物癌症治疗市场的重要驱动力。随着越来越多的家庭欢迎宠物进入他们的生活，这些伴侣动物被广泛认为是珍贵的家庭成员。这种情感连结培养了宠物主人的深刻责任感，以确保毛茸茸的同伴的福祉和健康。因此，宠物主人越来越愿意投资先进的癌症治疗方法来对抗疾病并提高宠物的生活品质。宠物主人为他们的宠物寻求尽可能最好的护理，导致对有效的癌症治疗方法的需求增加，这些治疗方法可以减轻宠物的痛苦并延长宠物的生命。

兽医肿瘤学的进展

近年来，由于技术进步和研究突破，兽医肿瘤学领域取得了显着进展。改进的诊断技术可以实现早期、准确的癌症检测，使兽医能够及时启动治疗。此外，人们对宠物癌症生物学认识的提升为标靶治疗、免疫疗法和新型治疗方式打开了大门。兽医肿瘤学家现在拥有一个扩展的癌症治疗工具箱，有助于制定适合每隻宠物独特状况的个人化护理计划。这些进步为面临癌症诊断的宠物主人带来了希望，并鼓励他们探索和选择先进且有效的癌症疗法。

不断增长的兽医医疗保健支出

人们对宠物的看法从单纯的动物伙伴转变为重要的家庭成员，导致兽医医疗保健支出模式显着转变。今天的宠物主人比以往任何时候都更愿意分配大量的财政资源来确保他们的宠物的健康和长寿。人们对现有癌症治疗方案的认识不断增强，以及对提供最佳护理的渴望，推动了宠物癌症治疗支出的增加。主人愿意投资最新、最有效的癌症治疗方法来对抗这种疾病，并改善毛茸茸的同伴的整体健康和幸福感。兽医医疗保健支出的激增进一步推动了宠物癌症治疗市场的发展，为宠物先进癌症治疗方案的研究、创新和开发创造了机会。

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球宠物癌症治疗市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：透过疗法

  • 化疗
    • 市场趋势
    • 市场预测
  • 放射治疗
    • 市场趋势
    • 市场预测
  • 免疫疗法
    • 市场趋势
    • 市场预测
  • 联合疗法
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：依动物种类

  • 猫
    • 市场趋势
    • 市场预测
  • 狗
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按癌症类型

  • 淋巴瘤
    • 市场趋势
    • 市场预测
  • 肥大细胞癌
    • 市场趋势
    • 市场预测
  • 黑色素瘤
    • 市场趋势
    • 市场预测
  • 乳癌和鳞状细胞癌
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 9 章：市场区隔：按最终用户

  • 兽医医院和临床药房
    • 市场趋势
    • 市场预测
  • 零售药局
    • 市场趋势
    • 市场预测
  • 网路药局
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 10 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第15章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • AB Science
    • Boehringer Ingelheim International GmbH
    • Elanco Animal Health Incorporated
    • ELIAS Animal Health LLC
    • Karyopharm Therapeutics
    • Pfizer Inc.
    • Regeneus Ltd.
    • Rhizen Pharmaceuticals AG
    • Torigen Pharmaceuticals Inc.
    • VetDC Inc.
    • Virbac
    • Zoetis Inc.
Product Code: SR112024A4472

The global pet cancer therapeutics market size reached US$ 295.2 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 635.9 Million by 2032, exhibiting a growth rate (CAGR) of 8.5% during 2024-2032. The increasing pet ownership rates and human-animal bond, advancements in veterinary medicine and research, and growing awareness about the availability and benefits of pet cancer therapeutics are some of the major factors propelling the market.

Pet cancer therapeutics are specialized medical treatments and drugs designed to diagnose, treat, and manage cancer in animals, particularly in dogs and cats. Similar to cancer treatments in humans, these therapeutics may include chemotherapy, radiation therapy, immunotherapy, targeted therapies, and palliative care. Veterinary oncologists administer these therapies to address various types of cancer in pets and improve their quality of life. As advancements in veterinary medicine continue, the availability and effectiveness of pet cancer therapeutics have increased, allowing pet owners to access comprehensive and compassionate care for their beloved animal companions diagnosed with cancer.

The rising willingness among pet owners to invest in advanced medical treatments, including cancer therapeutics, to ensure the well-being of their animal companions due to the increasing pet ownership and human-animal bond, will stimulate the growth of the market during the forecast period. Moreover, the growing prevalence of cancer in pets, owing to improved diagnostic capabilities and prolonged lifespan has augmented the demand for effective and specialized treatments. Apart from this, numerous advancements in veterinary oncology and research, including the development of more targeted and innovative cancer therapies for pets, have catalyzed the market growth. Additionally, the heightening awareness among pet owners about the availability and benefits of pet cancer therapeutics has led to early detection and intervention, propelling the market growth. Furthermore, the establishment of specialized veterinary oncology centers and the rising collaborations between veterinary and human oncologists that improve the accessibility and expertise in pet cancer care are contributing to the market growth.

Pet Cancer Therapeutics Market Trends/Drivers:

Increasing pet ownership and human-animal bond

The rise in pet ownership and the strengthening human-animal bond have become significant drivers in the market for pet cancer therapeutics. As more households welcome pets into their lives, these companion animals are widely considered cherished family members. This emotional connection fosters a deep sense of responsibility among pet owners to ensure the well-being and health of their furry companions. Consequently, there is a growing willingness among pet owners to invest in advanced cancer treatments to combat the disease and enhance the quality of life for pets. Pet owners seek the best possible care for their pets, leading to an increased demand for effective cancer therapeutics that can alleviate suffering and prolong their pets' lives.

Advancements in veterinary oncology

The field of veterinary oncology has witnessed remarkable progress in recent years, owing to technological advancements and research breakthroughs. Improved diagnostic techniques enable early and accurate cancer detection, empowering veterinarians to initiate timely treatment. Moreover, the rise in understanding of cancer biology in pets has opened doors to targeted therapies, immunotherapies, and novel treatment modalities. Veterinary oncologists now have an expanded toolbox of cancer treatments, facilitating the development of personalized care plans tailored to each pet's unique condition. These advancements instill hope in pet owners facing a cancer diagnosis for their beloved animals and encourage them to explore and opt for advanced and effective cancer therapies.

Growing veterinary healthcare expenditure

The changing perception of pets from mere animal companions to valued family members has led to a notable shift in spending patterns on veterinary healthcare. Pet owners today are more willing than ever to allocate substantial financial resources to ensure their pets' well-being and longevity. The growing awareness of available cancer treatment options and the desire to provide the best possible care have driven the increase in expenditure on pet cancer therapeutics. Owners are willing to invest in the latest and most effective cancer treatments to combat the disease and improve the overall health and happiness of their furry companions. This surge in veterinary healthcare spending further propels the pet cancer therapeutics market, creating opportunities for research, innovation, and the development of advanced cancer treatment options for pets.

Pet Cancer Therapeutics Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global pet cancer therapeutics market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on therapy, animal species, cancer type and end user.

Breakup by Therapy:

  • Chemotherapy
  • Radiation Therapy
  • Immunotherapy
  • Combination Therapy
  • Others

Chemotherapy dominates the market

The report has provided a detailed breakup and analysis of the market based on the therapy. This includes chemotherapy, radiation therapy, immunotherapy, combination therapy, and others. According to the report, chemotherapy represented the largest segment.

Chemotherapy is widely used as a standard treatment for various types of pet cancers. As a potent and systematic approach, chemotherapy targets rapidly dividing cancer cells, inhibiting their growth and spread. Its ability to treat a wide range of cancers, including lymphoma, mast cell tumors, and osteosarcoma, makes it a versatile and essential therapeutic option for veterinary oncologists.

Moreover, advancements in veterinary medicine have led to the development of more targeted and less toxic chemotherapy regimens, reducing adverse effects and improving the overall quality of life for pets undergoing treatment. The increasing prevalence of pet cancer cases, coupled with the growing awareness among pet owners about available treatment options, further contributes to the expansion of the chemotherapy segment.

Breakup by Animal Species:

  • Cats
  • Dogs
  • Others

Dogs hold the largest share in the market

A detailed breakup and analysis of the market based on the animal species has also been provided in the report. This includes cats, dogs, and others. According to the report, dogs accounted for the largest market share.

Dogs have a higher susceptibility to various types of cancers, mirroring human conditions. As a popular companion animal, dogs are commonly affected by cancers such as lymphoma, melanoma, and mammary tumors, among others. The similarities in cancer biology and tumor types between dogs and humans make dogs valuable models for studying cancer treatments, leading to advancements in therapeutic approaches that benefit both species. Veterinary oncology research conducted in dogs has resulted in the development of targeted therapies, immunotherapies, and novel treatment modalities that can be translated to human medicine. Furthermore, the strong emotional bond between pet owners and their dogs fosters a willingness to invest in their healthcare, including cancer treatments, thus driving the demand for effective pet cancer therapeutics.

Breakup by Cancer Type:

  • Lymphoma
  • Mast Cell Cancer
  • Melanoma
  • Mammary and Squamous Cell Cancer
  • Others

Mast cell cancer represents the most popular type of cancer

The report has provided a detailed breakup and analysis of the market based on the cancer type. This includes lymphoma, mast cell cancer, melanoma, mammary and squamous cell cancer, and others. According to the report, mast cell cancer represented the largest segment.

Mast cell tumors are one of the most common skin cancers in dogs, affecting various breeds and age groups. Their diverse behavior and variable response to treatments necessitate specialized therapeutics for effective management. Veterinary oncologists are continually researching and developing targeted therapies and immunotherapies specifically tailored to combat mast cell cancer. As a result, advancements in pet cancer therapeutics for mast cell tumors benefit dogs as well as contribute to the broader understanding and treatment of mast cell-related conditions in humans. The increasing awareness among pet owners about the need for early detection and comprehensive treatment options further drives the demand for innovative and efficient pet cancer therapeutics.

Breakup by End User:

  • Veterinary Hospitals and Clinical Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Veterinary hospitals and clinical pharmacies account for the largest market share

The report has provided a detailed breakup and analysis of the market based on the end-user. This includes veterinary hospitals and clinical pharmacies, retail pharmacies, online pharmacies, and others. According to the report, veterinary hospitals and clinical pharmacies represented the largest segment.

Veterinary hospitals and clinical pharmacies play a crucial role in driving the pet cancer therapeutics market by serving as key distribution and treatment centers for specialized pet cancer drugs and therapies. These institutions provide a centralized platform for pet owners to access a wide range of cancer treatments, including chemotherapy agents, targeted therapies, and immunotherapies. Veterinary hospitals collaborate with pharmaceutical companies and research institutions to stay updated on the latest advancements in pet cancer therapeutics, offering cutting-edge treatment options to their patients. Clinical pharmacies within these facilities ensure accurate drug dispensing and administration, adhering to precise dosages and treatment protocols. Their expertise in handling pet cancer therapeutics and providing personalized care contributes to improved treatment outcomes and enhances pet owners' confidence in seeking optimal cancer care for their beloved animal companions, ultimately driving the growth of the pet cancer therapeutics market.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance in the market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and Others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and Others) Latin America (Brazil, Mexico and Others), Middle East and Africa. According to the report, North America accounted for the largest market share.

North America held the biggest share in the market since the region has a high prevalence of pet ownership, and there is a strong bond between pet owners and their animals, leading to a greater willingness to invest in their healthcare, including cancer treatment. North America is also at the forefront of advancements in veterinary medicine and oncology research, resulting in the development of innovative and targeted pet cancer therapeutics. Veterinary hospitals and research institutions in the region collaborate closely with pharmaceutical companies to conduct clinical trials and introduce cutting-edge treatments to the market. Additionally, the presence of well-established veterinary healthcare infrastructure and a growing trend of personalized pet care contribute to the demand for specialized and effective cancer therapies. These factors collectively drive the growth of the market for pet cancer therapeutics in North America, making it a leading region in the industry.

Competitive Landscape:

The market is experiencing steady growth in recent years as various key players are focusing on the development of targeted therapies and immunotherapies tailored to specific types of pet cancers, aiming to enhance treatment effectiveness and reduce side effects. Numerous advancements in precision medicine by leading players have led to the identification of genetic and molecular biomarkers, allowing for personalized treatment approaches. Additionally, novel drug delivery methods, such as nanoparticles and liposomes, are being explored by manufacturers to improve drug stability and enhance tumor penetration. The integration of emerging technologies like artificial intelligence (AI) and machine learning (ML) in pet cancer research is revolutionizing data analysis and accelerating drug discovery processes. We also expect the market to witness new entrants, consolidation of product portfolios, rise in research and development (R&D) initiatives, and increased strategic collaborations to drive healthy competition within the pet cancer therapeutics domain.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • AB Science
  • Boehringer Ingelheim International GmbH
  • Elanco Animal Health Incorporated
  • ELIAS Animal Health LLC
  • Karyopharm Therapeutics
  • Pfizer Inc.
  • Regeneus Ltd.
  • Rhizen Pharmaceuticals AG
  • Torigen Pharmaceuticals Inc.
  • VetDC Inc.
  • Virbac
  • Zoetis Inc.

Recent Developments:

  • In July 2023, Boehringer Ingelheim International GmbH, a leading pharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for its innovative product, NexGard PLUS. This groundbreaking advancement in pet healthcare introduces a chewable tablet specifically designed to safeguard dogs from both internal and external parasites. The tablet contains a powerful combination of active ingredients, including afoxolaner, moxidectin, and pyrantel, which work synergistically to provide comprehensive protection against common parasitic threats.
  • In Dec 2022, Elanco Animal Health Incorporated, a prominent animal health company, announced a groundbreaking achievement with the FDA approval of Bexacat (bexagliflozin tablets). Bexacat marks a significant milestone as the first-of-its-kind oral treatment option for feline diabetes. This pioneering medication introduces a novel approach to managing diabetes in cats, addressing an unmet medical need in the veterinary industry. Bexacat, formulated as easily administered tablets, offers a promising solution for feline diabetes management, providing veterinarians and pet owners with an effective and convenient alternative to traditional insulin injections.
  • In Nov 2021, ELIAS Animal Health LLC, a leading biotechnology company specializing in cancer therapeutics for pets, announced a significant development in the field of oncolytic virotherapy. The company has successfully obtained an exclusive in-license from Genelux Corporation for their cutting-edge Oncolytic Vaccinia Virus Treatment. This groundbreaking treatment utilizes a modified vaccinia virus to target and destroy cancer cells in pet animals. By leveraging the virus's inherent ability to replicate and infect cancer cells while sparing healthy tissues, this therapy offers a novel approach to combat various types of pet cancers.

Key Questions Answered in This Report

  • 1. What was the size of the global pet cancer therapeutics market in 2023?
  • 2. What is the expected growth rate of the global pet cancer therapeutics market during 2024-2032?
  • 3. What are the key factors driving the global pet cancer therapeutics market?
  • 4. What has been the impact of COVID-19 on the global pet cancer therapeutics market?
  • 5. What is the breakup of the global pet cancer therapeutics market based on the therapy?
  • 6. What is the breakup of the global pet cancer therapeutics market based on thej animal species?
  • 7. What is the breakup of the global pet cancer therapeutics market based on cancer type?
  • 8. What is the breakup of the global pet cancer therapeutics market based on the end user?
  • 9. What are the key regions in the global pet cancer therapeutics market?
  • 10. Who are the key players/companies in the global pet cancer therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Pet Cancer Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Therapy

  • 6.1 Chemotherapy
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Radiation Therapy
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Immunotherapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Combination Therapy
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Animal Species

  • 7.1 Cats
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Dogs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Cancer Type

  • 8.1 Lymphoma
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Mast Cell Cancer
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Melanoma
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Mammary and Squamous Cell Cancer
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Veterinary Hospitals and Clinical Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AB Science
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
    • 15.3.2 Boehringer Ingelheim International GmbH
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 SWOT Analysis
    • 15.3.3 Elanco Animal Health Incorporated
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
    • 15.3.4 ELIAS Animal Health LLC
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Karyopharm Therapeutics
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Pfizer Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Regeneus Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Rhizen Pharmaceuticals AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Torigen Pharmaceuticals Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 VetDC Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
    • 15.3.11 Virbac
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Zoetis Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Pet Cancer Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Pet Cancer Therapeutics Market: Breakup by Therapy (in %), 2023
  • Figure 5: Global: Pet Cancer Therapeutics Market: Breakup by Animal Species (in %), 2023
  • Figure 6: Global: Pet Cancer Therapeutics Market: Breakup by Cancer Type (in %), 2023
  • Figure 7: Global: Pet Cancer Therapeutics Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Pet Cancer Therapeutics Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Pet Cancer Therapeutics (Chemotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Pet Cancer Therapeutics (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Pet Cancer Therapeutics (Radiation Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Pet Cancer Therapeutics (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Pet Cancer Therapeutics (Immunotherapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Pet Cancer Therapeutics (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Pet Cancer Therapeutics (Combination Therapy) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Pet Cancer Therapeutics (Combination Therapy) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Pet Cancer Therapeutics (Other Therapies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Pet Cancer Therapeutics (Other Therapies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Pet Cancer Therapeutics (Cats) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Pet Cancer Therapeutics (Cats) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Pet Cancer Therapeutics (Dogs) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Pet Cancer Therapeutics (Dogs) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Pet Cancer Therapeutics (Other Animal Species) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Pet Cancer Therapeutics (Other Animal Species) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Pet Cancer Therapeutics (Lymphoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Pet Cancer Therapeutics (Lymphoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Pet Cancer Therapeutics (Mast Cell Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Pet Cancer Therapeutics (Mast Cell Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Pet Cancer Therapeutics (Melanoma) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Pet Cancer Therapeutics (Melanoma) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Pet Cancer Therapeutics (Mammary and Squamous Cell Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Pet Cancer Therapeutics (Mammary and Squamous Cell Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Pet Cancer Therapeutics (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Pet Cancer Therapeutics (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Pet Cancer Therapeutics (Veterinary Hospitals and Clinical Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Pet Cancer Therapeutics (Veterinary Hospitals and Clinical Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: Global: Pet Cancer Therapeutics (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: Global: Pet Cancer Therapeutics (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Global: Pet Cancer Therapeutics (Online Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Global: Pet Cancer Therapeutics (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Global: Pet Cancer Therapeutics (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Global: Pet Cancer Therapeutics (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: North America: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: North America: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: United States: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: United States: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Canada: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Canada: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: Asia-Pacific: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: Asia-Pacific: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: China: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: China: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Japan: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Japan: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: India: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: India: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: South Korea: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: South Korea: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Australia: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Australia: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Indonesia: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Indonesia: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Others: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Others: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Europe: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Europe: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Germany: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Germany: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: France: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: France: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: United Kingdom: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: United Kingdom: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Italy: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Italy: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Spain: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Spain: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Russia: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Russia: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Others: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Others: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Latin America: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Latin America: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Brazil: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Brazil: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 85: Mexico: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 86: Mexico: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 87: Others: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 88: Others: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 89: Middle East and Africa: Pet Cancer Therapeutics Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 90: Middle East and Africa: Pet Cancer Therapeutics Market: Breakup by Country (in %), 2023
  • Figure 91: Middle East and Africa: Pet Cancer Therapeutics Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 92: Global: Pet Cancer Therapeutics Industry: SWOT Analysis
  • Figure 93: Global: Pet Cancer Therapeutics Industry: Value Chain Analysis
  • Figure 94: Global: Pet Cancer Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Pet Cancer Therapeutics Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Therapy (in Million US$), 2024-2032
  • Table 3: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Animal Species (in Million US$), 2024-2032
  • Table 4: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
  • Table 5: Global: Pet Cancer Therapeutics Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Pet Cancer Therapeutics Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Pet Cancer Therapeutics Market: Competitive Structure
  • Table 8: Global: Pet Cancer Therapeutics Market: Key Players